Back to results
US 2024/0197683 A1Published application
Use of ergothioneine (egt) for prevention and treatment of sepsis
AssigneeJiangsu University
InventorZhimin TAO
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeJiangsu University
InventorZhimin TAO
Estimating the term…
The present disclosure discloses use of ergothioneine (EGT) for the prevention or treatment of sepsis. The present disclosure studies the anti-inflammatory mechanism of ergothioneine in sepsis, aiming to provide a therapeutically effective dose and reveal the signaling pathway ergothioneine probably acts on in the treatment of sepsis, and provide experimental data support for the understanding of the mechanism behind the systemic inflammatory reactions of sepsis and for the use of ergothioneine as a new drug for treatment. The present disclosure also provides ergothioneine (EGT) loaded on a nanocarrier, and use thereof in the prevention or treatment of sepsis.
A method of prevention or treatment of sepsis or related disease in a subject, wherein the method comprises administering ergothioneine and/or a pharmaceutically acceptable derivative thereof to the subject.
A nanodrug, wherein the drug comprises a nano-sized pharmaceutical carrier, and ergothioneine and/or a pharmaceutically acceptable derivative thereof loaded on the carrier, wherein the nano-sized pharmaceutical carrier selects from organic nanoparticles, inorganic nanoparticles and nanoparticles of natural origin.
Dependencies are inferred from the claim text.